Lee Patient
About Lee Patient
Lee Patient is a Senior Principal Scientist at BenevolentAI in Cambridge, England, with over 20 years of experience in medicinal chemistry and a strong background in organic chemistry and pharmacology.
Current Role at BenevolentAI
Lee Patient is currently serving as a Senior Principal Scientist at BenevolentAI in Cambridge, England, United Kingdom. In this capacity, he leverages his extensive experience in medicinal chemistry to contribute to the company's innovative projects in drug discovery and development.
Previous Positions at BenevolentAI and Proximagen
Prior to his current role, Lee worked as a Principal Drug Discoverer at BenevolentAI from 2018 to 2020. Before that, he held the positions of Team Leader and Principal Scientist at Proximagen (now BenevolentAI), spanning from 2010 to 2018. At Proximagen, he played a crucial role in the company's transition to BenevolentAI and contributed significantly to the development of novel therapeutic agents.
Educational Background in Chemistry
Lee Patient holds a PhD in Organic Chemistry from the University of Southampton, which he completed between 2000 and 2003. He also earned a Master of Research in Organic Chemistry in 2000 and a Bachelor of Science in Chemistry with Pharmacology in 1999, all from the same institution. His academic training laid a strong foundation for his subsequent work in medicinal chemistry and drug discovery.
Professional Experience in Medicinal Chemistry
Lee has accumulated over 20 years of experience in medicinal chemistry, starting with roles as a Medicinal Chemist at IONIX PHARMACEUTICALS LIMITED and AMURA THERAPEUTICS LIMITED from 2003 to 2006. He then served as a Senior and later Principal Scientist at Cambridge Biotechnology Ltd from 2006 to 2010. His tenure at these companies involved significant contributions to the early-stage development of several pharmaceutical compounds.
Leadership and Team Management
Throughout his career, Lee has demonstrated a strong capability in leading scientific teams and projects. His leadership roles at Proximagen and later at BenevolentAI highlight his ability to guide and manage teams effectively within the biotech industry. His extensive experience ensures that he brings a wealth of knowledge and expertise to any project he oversees.